Antiplatelet therapy (APT) represents a major cornerstone in the secondary prevention of coronary artery disease, along with modifying patients' risk factors. Furthermore, it has been clear, since early unsuccessful regimens, including warfarin and dypiridamole with aspirin, that it is APT that stops coronary stents from clotting off and causing stent thrombosis.
However, as has been the case consistently since those early days, in patients with acute coronary syndromes (ACS) receiving stents there are competing indications for DAPT, since the evidence suggests a benefit from DAPT as a medical therapy in this setting. CURE was the first randomised trial to show that in a population of non-ST elevation ACS patients DAPT (using clopidogrel with aspirin) significantly decreased the rate of recurrent ischaemic events compared with aspirin monotherapy with placebo at a mean duration of therapy of 9 months. 1, 10 Importantly, 64 % of the 12,562 patients in this trial did not undergo revascularisation after randomisation. Specifically, there was a 20 % relative risk reduction in myocardial infarction, stroke or cardiovascular death with long-term DAPT use with no increase in life-threatening bleeds. In the CURE-PCI sub-study, there was a 25 % relative risk reduction in the composite of myocardial infarction or cardiovascular death with DAPT (≤12 months) compared with aspirin and placebo. 10 It was largely based on this evidence that 12 months' DAPT became the recommended default for stents post-ACS. However, given that there was a 4 % per year incidence of significant bleeding in the CURE study in the cohort on DAPT, there was clearly a balance to be struck between longer DAPT to reduce ischaemic events and shorter DAPT to minimise bleeding, which itself has been shown to be an independent risk factor for worse prognosis. 1, 10 That tension between ischaemic and bleeding events is indeed the driver for our current debate, just as it has been since stents were first implanted. In addition, the suspicion that patients receiving stents in elective, stable settings need DAPT for less time than patients presenting with ACS consistently remains a driver for reducing duration of DAPT therapy.
Finally, the consistent iterative technologically-driven evolutions in the design of stents represent a further confounding factor in determining the optimal duration of DAPT.
DAPT in DES Patients -a Moving Target!
The main limitation of BMS was an exaggerated inflammatory healing response, leading to excessive neointimal proliferation and restenosis.
Clinically, this led to around 10 % of patients representing with recurrent symptoms. Randomised trials demonstrating the dramatic reduction in target vessel revascularisation, due to restenosis, with DES compared with BMS has revolutionised patient care. [7] [8] [9] However, the cost of this clinical benefit was a demonstrably higher risk of ST in DES1 versus BMS, which was attritional over time. 11 As a result, international guidelines were changed in 2007 to indicate that all patients receiving DES should receive DAPT for "at least 12 months". 12 The default regimen was even more strongly set, albeit still based upon very little actual evidence. 12 More recently, however, the continuous iteration of DES design has yielded devices with properties likely to reduce the risk of ST: thinner struts; less, or shorter duration, polymer; more sophisticated drug and dosing profiles. As a result of observational data confirming this notion, second-and third-generation DES (DES 2) have been the focus of a series of randomised trials testing shorter duration DAPT versus longer regimens. [13] [14] [15] [16] [17] [18] [19] [20] These trials are disparate in detail regarding type of stent, mix of patient presentation, duration of the DAPT regimens being compared, type of P2Y12 inhibitor and composite primary endpoint. 19 However, they share some common features. First, none were powered to look at ST as a primary isolated endpoint. Second, they generally have demonstrated no advantage of a longer DAPT duration compared with shorter. Furthermore, in many cases, they demonstrated significantly higher rates of major bleeding in the longer DAPT groups.
It is notable that in some randomised trials, the duration of DAPT could be as short as 3 months with some types of DES 2 [16] [17] without any disadvantage in terms of ischaemic endpoint. The accumulated body of this evidence has pointed interventionalists towards shorter duration DAPT in DES 2 patients. This is, indeed, reflected in the 2014 ESC guidelines 21 now recommend DAPT for only 6 months in stable patients receiving DES 2, but stick to 12 months' DAPT after ACS. A seemingly logical and intuitive evolution in what we all thought we knew about DAPT with modern DES 2 was then challenged by the DAPT trial.
The DAPT Trial -Turning What We Thought We Knew on its Head
In the DAPT study 229,661 patients with a mix of elective and ACS presentations, who had undergone PCI using DES 1 and DES 2 and who had had an uneventful period of DAPT treatment for 12 months already, were then randomised to either a further 18 months of DAPT or aspirin plus placebo. There was a significant reduction in both ST (p<0.001), a specified co-primary endpoint and major adverse CV and cerebrovascular events (p<0.001) in the prolonged duration DAPT group compared with aspirin monotherapy. However, there was a significant increase in important bleeding in the 30-month DAPT group (p=0.001). Another interesting observation was that although allcause mortality was no different between the groups, the prolonged DAPT group had a significantly higher rate of non-cardiovascular death (p=0.002). But also, despite the temptation to put the increased incidence of non-cardiovascular death down to statistical quirk, this raises alarm bells given the large number of patients worldwide being treated in this way. The meta-analysis by Palmerini et al., which includes the DAPT trial, just published in The Lancet, 23 confirms that we should indeed take a cautious approach to a universal switch to prolonged DAPT after DES. The analysis includes more than 32,000 patients and confirms that there is a 33 % lower rate of non-cardiovascular mortality in the shorter duration DAPT arm compared with longer duration, and this actually drives a hazard ratio of 0.82 for all-cause mortality in the shorter duration group. On the other side of the coin, a meta-analysis by Elmariah et al., which involved 14 studies including the DAPT study, showed that extended-duration was not associated with a difference in the risk of all-cause, cardiovascular or noncardiovascular death compared with aspirin alone or short-duration. 24 
DAPT after DES -What Should We Do Now?
Although the evidence apparently presents a chaotic and discrepant picture, some themes regarding our DAPT strategy for DES patients are manifest. First, that if DAPT is used for longer, the risk of ischaemic events, including ST, will be reduced. Second, that this reduction will be at the expense of increased bleeding. Third, strong circumstantial evidence suggests that if DAPT is used for more than a year, non-CV mortality is higher -perhaps because of the excess in important bleeding.
Taking these concepts together, it seems sensible to stick, for now, with a default of 12 months' DAPT for most patients, pending further specific data.
DAPT after DES -What Do We Need to Know for the Future?
In order to make progress in this field, we need to address more precisely some unanswered questions. These are questions that cannot be answered in trials that recruit patients with a variety of elective and ACS presentations using different generations of stent and different DAPT constituents. We need answers to these questions via appropriately powered randomised trials:
1. Using specific DES 2 (i.e. only one type in each trial), can DAPT be safely employed for 6, 3 or 1 month(s) in elective patients? 2. Using specific DES 2, can DAPT be safely employed for 6 or even 3 months in ACS patients?
3. Do we actually need DAPT anyway? The results of trials like GLOBAL LEADERS, 25 randomising DES patients to ticagrelor alone compared with DAPT after a certain period of aspirin plus ticagrelor, could revolutionise our thinking about this field completely.
Finally, what shines out of a forensic assessment of the current evidence about DAPT after DES is this: the concept that we can have wholesale strategies for APT for large groups of patients is fundamentally flawed.
The real challenge is to develop personalised pathways of care that take into account individual risk of ischaemic events, bleeding and, probably, also their response to APT using point-of-care tests of platelet reactivity. [26] [27] It is time to discard our palpably inadequate "one-sizefits-all" approach and develop patient-specific strategies. Such an individualised approach might well eliminate many of the adverse effects we currently witness. n
